Rezolute (Rezolute) Float Percentage Of Total Shares Outstanding : 42.23% (As of Jun. 06, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Rezolute Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rezolute's float shares is 16.95 Mil. Rezolute's total shares outstanding is 40.14 Mil. Rezolute's float percentage of total shares outstanding is 42.23%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rezolute's Insider Ownership is 21.86%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rezolute's Institutional Ownership is 39.56%.

Rezolute Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Rezolute's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	16.95	/	40.14
	=	42.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rezolute (Rezolute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065

Website

https://www.rezolutebio.com

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Executives

Brian Kenneth Roberts	officer: Chief Medical Officer	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Gil M Labrucherie	director	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Wladimir Hogenhuis	director	60 LEVERONI COURT, NOVATO CA 94949
Nerissa Kreher	director	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Handok, Inc.	10 percent owner	132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Philippe Fauchet	director	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim	director	C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc.	10 percent owner	700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller	officer: VP Finance & CAO	C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young-jin Kim	director	49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Young Chul Sung	director	101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola	officer: Chief Financial Officer	111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp	10 percent owner	2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch	director	C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089
Morgan Fields	officer: Chief Accounting Officer	890 SANTA CRUZ AVE., MENLO PARK CA 94025